A Phase I Study of p28 in Children with Recurrent or Progressive Brain Tumors

Protocol
13-207
Full Title
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 ubiquitination in Pediatric Patients with Recurrent or Progressive CNS Tumors (PBTC-041)
Phase
I
Disease Status
Relapsed/Refractory
Purpose

Brain tumors in children are often challenging to treat successfully. The purpose of this Pediatric Brain Tumor Consortium study is to find the highest dose of an investigational drug called p28 (NSC745104) that can be given safely in children whose brain tumors have come back or continued to grow despite treatment.

Many cancer cells have a protein called p53 that does not work properly. This protein normally puts the breaks on rampant cell growth, and when it does not function well, cells can continue to grow uncontrollably (as cancer cells do). The p28 drug is designed to find and kill cancer cells with dysfunctional p53. It is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • This study is open to patients ages 3 to 21.
  • Patients must have a brain tumor that has returned or continued to grow despite treatment. Patients with certain tumor types (such as ependymoma) may not be eligible.
  • Patients should have recovered from the serious side effects of prior therapies before entering the study.

For more information and to inquire about eligibility for this study, please contact Dr. Ira Dunkel at 212-639-2153.

Disease(s)
Pediatric Brain Tumors: Brain Cancer
Locations
Related Diseases